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School of Social & Community Medicine, University of Bristol, Bristol, UKA B S T R A C TObjectives: A new method is presented for both synthesizing treat-
ment effects on multiple outcomes subject to measurement error and
estimating coherent mapping coefﬁcients between all outcomes. It
can be applied to sets of trials reporting different combinations of
patient- or clinician-reported outcomes, including both disease-
speciﬁc measures and generic health-related quality-of-life measures.
It is underpinned by a structural equation model that includes
measurement error and latent common treatment effect factor.
Treatment effects can be expressed on any of the test instruments
that have been used. Methods: This is illustrated in a synthesis of
eight placebo-controlled trials of TNF-α inhibitors in ankylosing
spondylitis, each reporting treatment effects on between two and ﬁve
of a total six test instruments. Results: The method has advantages
over other methods for synthesis of multiple outcome data, including
standardization and multivariate normal synthesis. Unlike standard-
ization, it allows synthesis of treatment effect information from testsee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2013.12.006
ristol.ac.uk.
ndence to: A.E. Ades, University of Bristol, Canynginstruments sensitive to different underlying constructs. It represents
a special case of previously proposed multivariate normal models for
evidence synthesis, but unlike the former, it also estimates mappings.
Combining synthesis and mapping as a single operation makes more
efﬁcient use of available data than do current mapping methods and
generates treatment effects that are consistent with the mappings. A
limitation, however, is that it can only generate mappings to and from
those instruments on which some trial data exist. Conclusions: The
method should be assessed in a wide range of data sets on different
clinical conditions, before it can be used routinely in health technol-
ogy assessment.
Keywords: congeneric tests, cross-walking, mapping, multioutcome
synthesis.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The effects of new treatments in randomized controlled trials are
often measured by test instruments that record patient- or
clinician-reported “subjective” outcomes. Typically, there are a
range of test instruments available to investigators. For example,
the efﬁcacy of treatments for depression may be evaluated by the
Hamilton [1], Beck [2], or Montgomery-Asberg scales [3]. These
would all be regarded as measuring approximately the same
underlying construct. In dermatological or rheumatic illnesses,
or for many cancers, there is also a wide range of patient- or
clinician-reported instruments available, but most are designed
to measure different disease-related constructs. In ankylosing
spondylitis, for example, randomized trials routinely investigate
treatment effects on pain, using a numeric rating scale or a
continuous visual analogue scale (VAS); on disease progression,
using the Bath Ankylosing Spondylitis Disease Activity Index [4];
and on patients’ daily life, using the Bath Ankylosing Spondylitis
Functional Index [5].
One can further distinguish between the above disease-
speciﬁc measures (DSMs) and generic health-related quality-of-
life (HRQOL) instruments that are designed to be applied to
almost any condition, such as the Euroqol ﬁve-dimensional(EQ-5D) questionnaire [6] and the multipurpose short-form 36
health survey [7].
The existence of so many test instruments raises a number of
issues in meta-analysis, the statistical pooling of treatment
effects reported in different trials on the same treatments [8–
10]. Several different approaches have been described. Stand-
ardization (division of treatment effects by the sample SD) allows
synthesis of different instruments on a common scale [11]. A
disadvantage is that division by the sample standard error can
only add to heterogeneity. It also assumes that all the measures
are equally sensitive to the treatment effect. Composite outcomes
can be created through linear combinations of treatment effects
on different instruments [9–12], although these are seldom used
because investigators prefer outcomes to be measured on famil-
iar scales. Various forms of multivariate meta-analysis based on
within- and between-trial correlation [13–18] have also been
proposed. These approaches have different properties, objectives,
and scope of application: we return to discuss them in greater
detail later.
A second, quite different, problem is the “mapping” from
treatment effects on DSMs to treatment effects on generic
HRQOLs. This is widely used in health technology assessment
(HTA), when estimates of treatment effects on generic HRQOLociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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treatment effect data are available only on DSMs. Usually, an
externally sourced mapping coefﬁcient is used to translate the
treatment effect on a DSM into a treatment effect on a generic
HRQOL scale such as the EQ-5D questionnaire [19,20]. These mapp-
ings are usually derived from a regression based on an external
“estimation” dataset. The regression equation is then applied to
“source” (DSM) estimates to generate “target” (generic HRQOL)
estimates, at the level of either a mean effect or individual patient
data [20,21]. We will return to consider the way mappings are
derived and used in HTA in the discussion.
This article presents a method for multioutcome synthesis
based on the hypothesis that for a deﬁned population of patients
undergoing a given type of treatment, mapping coefﬁcients,
deﬁned as the ratios of the true treatment effects δjr, δjs, δjt on
instruments r, s, t, remain approximately constant across trials j:
δjs
δjr
¼βr4 s ð1Þ
It follows from this deﬁnition that mappings are invertible and
transitive [22].
βr4 s¼
1
βs4 r
, and βr4 sβs4 t¼βs4 t ð2Þ
The advantage of the proposed method over other forms of
multioutcome synthesis, and over previous methods for mapping,
is that simultaneously it “borrows strength” across correlated
outcomes, both within and between trials, it allows investigators
to express the pooled estimates of treatment effects on any scale,
but without introducing further heterogeneity, and it estimates
the mapping coefﬁcients between treatment effects, subject to
invert ability and transitivity constraints, as well as estimates
treatment effects that are consistent with the mappings.
We begin by describing an illustrative data set, and then
describe the statistical methods, followed by a short description
of the results. In discussion, we contrast the proposed model
with existing approaches to multioutcome synthesis and with
current approaches to mapping in HTA. Some technical details
can be found in appendices, available as Supplemental Material
found at http://dx.doi.org/10.1016/j.jval.2013.12.006.Table 1 – Treatment effects on change from baseline, rel
trials of TNF-α inhibitors in ankylosing spondylitis.*
Trial Treatment Weeks PAIN-VAS BA
1. Gorman (2002)
[25]
ETA 16 4.15 (0.803) 2.2
2. Brandt (2003) [26] ETA 6 1.7
3. Davis (2003) [27] ETA 24 1.83 (0.410) 1.41
4. van der Heijde
(2006) [28]
ADA 12 1.956 (0.350) 1.414
5. Braun (2002) [29] INF 12 2.0
6. van der Heijde
(2005) [30]
ADA 24 1.5
7. van der Heijde
(2009) [31]
INF 24 2.6 (0.333) 1.7
8. Inman (2008) [32] GOL 50 12 2.7 (0.412) 1.5
8. Inman (2008) [32] GOL 100 12 2.8 (0.424) 1.6
ADA, adalimumab 40 mg; ASQOL, Ankylosing Spondylitis Quality of Life
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional I
inﬂiximab 5 mg; SF-36 MCS, short-form 36 health survey mental comp
component summary; VAS, visual analogue scale.
* ASQOL, 0 to 18 scale; BASDAI, 0 to 10 scale; BASFI, 0 to 10 scale; PAIN-Methods
Materials: TNF-α Inhibitors in Ankylosing Spondylitis
The manufacturers of the TNF-α inhibitor golimumab (Simponi)
submitted a cost-effectiveness analysis of the product in the
treatment for ankylosing spondylitis to the National Institute for
Health and Clinical Excellence in November 2010 [23]. The sub-
mission included network meta-analyses [24] of several placebo-
controlled trials of the TNF-α inhibitors golimumab, etanercept,
inﬂiximab, and adalimumab. Eight trials [25–32] reported between
one and ﬁve of the following six test instruments: Pain on a VAS;
Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing
Spondylitis Disease Activity Index, the Ankylosing Spondylitis
Quality of Life scale [33,34], and the short-form 36 health survey
physical and mental components summaries. We extracted the
mean change scores on each arm (follow-up assessment minus
baseline score) and the standard error of the change scores on
their original scales (see Appendix A in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2013.12.006). If results
were reported at more than one follow-up time, we chose just
the ﬁrst. The ﬁnal data set is shown in Table 1. One study was a
three-arm trial.
Our methods require information on the between-test within-
study correlations. For this purpose, we used the Evaluation of
Ankylosing Spondylitis Quality of Life cohort study [33,34]. This
examined 612 individuals suffering from ankylosing spondylitis,
using the six instruments reported in the randomized controlled
trials.Common Treatment Factor Model
A common factor model [22,35] provides the underlying rationale
for our approach. Consider data on individuals t randomized to
an active treatment in trial j and individuals c randomized to
placebo. Two outcomes are observed, measured by instruments r
and s. We can express the observed patient outcomes Yr and Ys
on these instruments in terms of a standardized common latent
variable y and error terms εr, εs ? y that are orthogonal to y butative to placebo, and their standard errors in eight
SFI BASDAI SF-36 PCS SF-36
MCS
ASQOL
(0.772)
(0.80) 2.2 (0.553)
(0.285) 1.91 (0.258)
(.267) 1.8 (0.283)
(0.561) 2.6 (0.433) 8.3 (5.74) 3.85 (4.33)
(0.236) 1.8 (0.286) 5.2 (1.026) 1.6 (1.162) 2.4 (0.488)
(0.230) 2.5 (0.274) 9.4 (0.957) 0.7 (1.045)
(0.264) 4.9 (1.164) 1.4 (1.023)
(0.274) 6.0 (1.069) 3.6 (1.252)
scale; ETA, etanercept 25 mg; BASDAI, Bath Ankylosing Spondylitis
ndex; GOL 50, golimumab 50 mg; GOL 100, golimumab 100 mg; INF,
onent summary; SF-36 PCS, short-form 36 health survey physical
VAS, 0 to 10 scale; SF-36 PCS and SF-36 MCS, 0 to 100 scale.
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Yjcr¼arþbrycþcrεjcr
Yjtr¼arþbrðytþδjÞþcrεjtr
Yjcs¼asþbsycþcsεjcs
Yjts¼asþbsðytþδjÞþcsεjts
Yc, Yt, εjcr, εjtr, εjcs, εjtsNð0, 1Þ ð3Þ
The coefﬁcients (ar, as) are the arbitrary intercepts, and
br, cr, bs, cs are factor loadings for the latent variable y and error
terms εr, εs on each scale. The factor y represents the common
treatment construct, the component of the test that is sensitive to
treatment. The speciﬁc error components εr, εs comprise both
measurement error and other components that are (by deﬁnition)
insensitive to treatment. A treatment effect δj on the common
latent factor y will manifest as a treatment effect brδj on instru-
ment r and bsδj on instrument s. The mapping coefﬁcient from
r to s is therefore βr4 s¼bs=br. Clearly, mappings derived from
this model have the properties in (2). If the error variables εr, εs
were also orthogonal, then r and s would qualify as congeneric
tests [36] in a classical measurement theory [37] formulation.
Note the implication that the mapping ratio will remain constant
as δj varies from trial to trial. This assumption can be relaxed.
Model (3) could be extended to a case in which there are separate
treatment effects on k orthogonal, treatment-sensitive con-
structs, y1, y2, …, yk. Although the mapping coefﬁcients will now
be ratios of linear functions of loadings, they will still be
estimated by ratios of treatment effects.
The common factor model (3) plays no direct role in the meta-
analytic approach to mapping and synthesis we now describe,
but it provides an underlying rationale for our approach to
mapping, and explains why it leads to a synthesis with different
properties to other multivariate methods [13,14].
Data Likelihood
In each trial j, for an instrument r, the mean outcomes at follow-
up and at baseline are, dropping the subscript j, YrTF and YrTB,
respectively, in the treatment arm and YrCF, and YrCB, in the
control arm, with variances VrTF, VrTB, VrCF, VrCB and sample sizes
nT and nC. What is reported varies somewhat from trial to trial.
The variances and covariances [38] of the mean treatment effects
on change scores on instruments r and s are as follows:
D^m¼ðYmTFYmTBÞðYmCFYmCBÞ, Smm¼VarðD^mÞ¼
VmT
nT
þ VmC
nC
,
Srs¼CovðD^r, D^sÞ¼ρrs
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
VrTVsT
p
nT
þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
VrCVsC
p
nC
 
ð4Þ
where ρrs is the correlation between change scores on instruments
r and s. In trials in which the variance of the change scores
on each arm, VmT, VmC, is not reported, we have used theTable 2 – Correlation matrix from the EASi-QoL study, ba
complete data.
Outcomes Pain-VAS BASFI BASDA
Pain-VAS 1 0.703 0.852
BASFI 0.703 1 0.811
BASDAI 0.852 0.811 1
ASQOL 0.738 0.829 0.856
SF-36 PCS 0.668 0.842 0.751
SF-36 MCS 0.493 0.463 0.583
ASQOL, Ankylosing Spondylitis Quality of Life scale; BASDAI, Bath Ank
Spondylitis Functional Index; EASi-QoL, Evaluation of Ankylosing Spond
component summary; SF-36 PCS, short-form 36 health survey physical cvariances at baseline and follow-up, following the common
practice of assuming a 0.5 correlation between baseline and
follow-up scores, on every outcome [39].
None of the trials report correlations between test instru-
ments. We show (Appendix B in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2013.12.006) that if we assume
Corr(YrB,YsF|YsB) ¼ 0, meaning that the correlation between YrB
and YsF comes only through the correlation between YrB and YsB,
then the correlation between change scores is equal to the
correlation between cross-sectional scores. Information on the
latter was made available from the Evaluation of Ankylosing
Spondylitis Quality of Life study [33] (Table 2). Sensitivity anal-
yses were run to assess the effect of increasing or decreasing ρrs
by 10%.
The likelihood of a treatment effect on a single outcome on
instrument m in the two-arm trial j can therefore be represented
as D^jmNðδjm, Sj,mmÞ. If we consider the case in which M outcomes
are reported, 2rMr6, this has a multivariate normal likelihood,
D^jMVNðδj, SjÞ. The diagonal elements for instrument r are Sj,rr,
and the off-diagonal elements for instruments r and s are Sj,rs, as
deﬁned in (4). The likelihood for multiarm trials is shown in
Appendix C in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2013.12.006.
Models for Treatment Effects and Mappings
Pain-VAS was chosen (arbitrarily) as the “baseline” test instru-
ment, indexed m ¼ 1. The model for the treatment effect on
instrument 1 in trial j is a standard random-effects model,
δj1Nðμ1, s21Þ. In a three-arm trial comparing treatment h and k
with placebo, the treatment effects relative to placebo, δj,k,1 and
δj,h,1, are correlated. Assuming homogeneous variances [40,41],
the treatment effects relative to placebo have a multivariate
normal distribution:
δj,h,1
δj,k,1
 !
ΜVΝ
μ1
μ1
 !
s21 s
2
1=2
s21=2 s
2
1
 ! !
ð5Þ
In a Bayesian framework, we assign vague priors to the hyper-
parameters: μ1  N(0, 1002) and s1  U(0, 10).
To map treatment effects on each of the M instruments into
treatment effects on every other instrument, M(M  1)/2 map-
pings must be estimated. Because of the constraints embodied in
Equation 2, (M  2)(M  1)/2 of these can be deﬁned from the
remaining M  1. This makes it possible to identify all 15
mappings from the eight trials. We specify the mappings from
Pain-VAS to the ﬁve other instruments as “basic” [42] parameters
that are assigned vague priors, while the remaining 10 mappings
are “functional” parameters deﬁned in terms of the ﬁve basic
ones. Note that the relative signs of the mappings, reﬂected in
the correlations (Table 2), are considered “known.”sed on 571 patients with ankylosing spondylitis with
I ASQOL SF-36 PCS SF-36 MCS
0.738 0.668 0.493
0.829 0.842 0.463
0.856 0.751 0.583
1 0.785 0.654
0.785 1 0.339
0.654 0.339 1
ylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing
ylitis Quality of Life; SF-36 MCS, short-form 36 health survey mental
omponent summary; VAS, visual analogue scale.
Table 3 – Posterior summaries of mapping, treat-
ment effect and variation parameters, and good-
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β1→mNð0,1002Þ, β1→m¼SignðAbsðβ1→mÞÞ, m¼2…Mness-of-ﬁt statistics under ﬁxed and random
mapping models.*
Parameters Fixed
mapping
Random
mapping
Treatment effect on Pain-VAS
Mean, μ1 2.26 (0.24) 2.30 (0.25)
Between-study SD, s1 0.40 (0.031, 1.04) 0.42 (0.028, 1.10)
Mappings from Pain-VAS to:
BASFI, β1→2 0.68 (0.038) 0.68 (0.056)
BASDAI, β1→3 0.94 (0.039) 0.92 (0.072)
ASQOL, β1→4 1.21 (0.12) 1.21 (0.28)
SF-36 PCS, β1→5 2.96 (0.19) 2.88 (0.30)
SF-36 MCS, β1→6 0.60 (0.23) 0.59 (0.24)
CV for mappings,
between-study, ϕ
– 0.130 (0.055, 0.25)
Goodness-of-ﬁt statistics
Residual deviance, D 57.6 35.8
Effective number of
parameters, pD
21.3 17.9
Deviance information
criterion, DIC
78.8 53.8
ASQOL, Ankylosing Spondylitis Quality of Life scale; BASDAI, Bath
Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Anky-
losing Spondylitis Functional Index; CV, coefﬁcient of variation;
SF-36 MCS, short-form 36 health survey mental component sum-
mary; SF-36 PCS, short-form 36 health survey physical component
summary; VAS, visual analogue scale.
* For mappings and treatment effect, posterior means (SDs); for
SDs, posterior medians (2.5, 97.5 centiles).βr→s¼βr→1β1→s¼
β1→s
β1→r
, r¼2…ðM1Þ, s¼ðrþ1Þ…M ð6Þ
This model (6) is a “ﬁxed mapping” model. In the event, this did
not ﬁt the data well, a random mapping model was constructed,
in which the mapping coefﬁcient βj,r→s applying in any trial j is
drawn from a normal distribution:
βj,r→sNðβr→s,s2r→sÞ ð7Þ
whose means βr-s were given the same priors as in (6), and have
the same properties (2). Regarding the variances s2r→s, we
hypothesize that the coefﬁcient of variation (CV) of each map-
ping, the between-trials SD divided by the mean, is the same on
each instrument, where ϕ is the CV:
s2r→s¼β2r→sϕ2, ϕUð0, 1Þ ð8Þ
The model assumes that each trial samples all M ¼ 6 treatment
effects from a multivariate normal distribution, but some test
instruments are missing at random. As such, the model gener-
ates predicted treatment effects δjm¼β1-mδj1 on each instrument
on each trial, and enables us to report mean treatment effects
μm¼β1→mμ1 and between-trial SDs sm¼Absðβ1→mÞs1 on each
instrument.
Estimation was carried out by Markov Chain Monte Carlo
using WinBUGs [43]. The code and data set are set out in full in
Appendix D in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2013.12.006. Goodness of ﬁt was assessed via the
posterior mean residual deviance [44]. The residual deviance for a
multivariate normal likelihood is, summing over trials j, as
follows
D¼∑
j
ðD^jδjÞS1j ðD^jδjÞ ð9Þ
Model ﬁt is usually considered to be adequate when the posterior
mean D is approximately equal to the number of data points, 32
in the Table 1 data set. We also calculated the deviance informa-
tion criteria [44], a measure of goodness of ﬁt penalized by the
number of effective parameters. The latter was calculated by
calculating goodness of ﬁt at the posterior mean of the outcomes
predicted by the model [24]. Further diagnostic checks were
carried out: ﬁrst, we looked at the posterior mean residual
deviance, the Mahanobolis distance, for each trial separately,
and second, we examined residuals (observed minus predicted
treatment effect for every treatment effect, to check that, for each
test instrument, the predicted treatment effects were not system-
atically too high or too low).
Convergence, based on standard statistical criteria [45],
occurred within 20,000 in the ﬁxed mapping model, and for most
parameters within 30,000 in the random mapping model. One
parameter required 80,000 samples to converge. Posterior sum-
maries for both ﬁxed and random mapping models have been
based on 100,000 samples from each of ﬁve chains, having
discarded the ﬁrst 100,000.Results
Posterior summaries of treatment effects on Pain-VAS are shown
in Table 3. The mean treatment effect and its precision, and the
between-trials variation, are relatively insensitive to whether
ﬁxed or random models are chosen for the mapping. The ﬁxed
mapping model, however, ﬁtted poorly, with residual deviance
D ¼ 57.6 compared with 34 data points. Globally, the random
mapping model ﬁtted adequately with a D of 35.8. The number of
effective parameters in the random mapping model was, unusu-
ally, less than in the ﬁxed mapping model. This suggests that thenumber of additional effective mapping parameters is relatively
few and that their presence allows greater “shrinkage” of treat-
ment effects toward their mean value. The deviance information
criterion, which is the sum of the residual deviance and the
number of parameters, therefore strongly favors the random
mapping model.
The estimated mapping ratios from each instrument to Pain-
VAS are also presented in Table 3. It is evident that the mapping
model has little effect on their mean value. As might be expected,
their posterior precision is somewhat lower in a randommapping
model, but even under random mapping they are estimated with
a relatively high precision. Furthermore, the degree of variation
in mappings from trial to trial is relatively low, with a CV ϕ
showing a median value of only 0.13, with an upper (97.5%)
credible limit of 0.24. This indicates a between-studies SD that is
only, on average, 13% of the mean.
The ability of the method to generate pooled treatment effects
on any of the scales is illustrated in Table 4.
We developed two model diagnostic procedures. The ﬁrst
(Table 5) looks at the goodness of ﬁt in each trial. The residual
mean deviances are compared with their expected values, which
is the number of data points. The ﬁt of each trial seems adequate.
The second plots the residuals (Fig. 1) and allows us to check that
none of the outcomes are associated with a systematic error. We
explored the effect of raising or lowering the assumed correla-
tions between change scores on different instruments. Making all
the correlations 10% smaller, or 10% greater without changing
their sign, had little effect (o1%) on the posterior means of either
the treatment effect or the mapping coefﬁcient distributions.
Increasing the correlation decreases the total amount of infor-
mation on the treatment effect but increases the information on
mappings, and this is reﬂected in slight changes in posterior SDs.
Table 4 – Posterior summaries of treatment effects
on each of the instruments, and between-study SDs,
under the random mapping model.
Mean treatment
effect (SD)
l1, 2, 3, 4, 5, 6
Between-studies mean
SD (2.5, 50, 97.5
percentiles) r1, 2, 3, 4, 5, 6
Pain-VAS 2.30 (0.25) 0.42 (0.03, 0.38, 1.10)
BASFI 1.55 (0.19) 0.28 (0.02, 0.25, 0.75)
BASDAI 2.11 (0.25) 0.39 (0.03, 0.35, 1.03)
ASQOL 2.78 (0.70) 0.51 (0.03, 0.44, 1.44)
SF-36 PCS 6.60 (0.89) 1.21 (0.08, 1.07, 3.18)
SF-36 MCS 1.36 (0.59) 0.25 (0.01, 0.20, 0.79)
ASQOL, Ankylosing Spondylitis Quality of Life scale; BASDAI, Bath
Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Anky-
losing Spondylitis Functional Index; SF-36 MCS, short-form 36
health survey mental component summary; SF-36 PCS, short-form
36 health survey physical component summary; VAS, visual
analogue scale.
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residual (max 10%), between-trial variation in treatment (10%–
20%), and between-trial CV in mappings (7%–10%).Discussion
The method provides a new solution to two problems, hitherto
seen as unrelated: multioutcome synthesis and between-
outcome mapping. In this section, we begin by focusing attention
on speciﬁc results obtained with these data, and consider some
alternative models that might have been used. We then compare
properties of the proposed approach with current methods in the
two ﬁelds of multioutcome synthesis and mapping. We end with
comments on limitations and further research needs.
We assumed a standard random treatment effect model, but
other treatment models could have been ﬁtted. A ﬁxed treatment
effect model, not shown here, ﬁtted very poorly. An alternative
treatment model that could be ﬁtted, if the objective is to
compare the efﬁcacy of different biologics, is a network meta-
analysis [24]. We would anticipate that mappings, which depend
on within-trial information, would be relatively insensitive to
treatment effect models, which are driven by between-trial
information. Mappings could still be estimated if we assumed
that treatment effects in each trial were entirely unrelated, butTable 5 – Residual mean deviance by trial.
Trial Mean residual
deviance
Number of data
points
1. Gorman (2002)
[25]
4.8 2
2. Brandt (2003) [26] 0.7 2
3. Davis (2003) [27] 3.0 3
4. van der Heijde
(2006) [28]
2.2 3
5. Braun (2002) [29] 2.6 4
6. van der Heijde
(2005) [30]
4.1 5
7. van der Heijde
(2009) [31]
5.9 5
8. Inman (2008) [32] 12.4 8then pooled treatment effects could not be estimated. Note,
however, that mappings between instruments can be accurately
estimated only if there is a “network” of connections between
them. A trial reporting an “unconnected” instrument could be
included, but the between-trial variation in treatment
effect would be confounded by the between-trial variation in
mapping.
The randommapping model ﬁtted each trial, and we found no
signs of systematic deviation from the model. The degree of
between-trial variation in mapping ratios will depend entirely on
the data. In this data set, although we can deﬁnitely reject the
null hypothesis that mappings are exactly the same from one
trial to the next, the degree of between-trial variation in map-
pings was relatively small, with a CV of only 13%. This lends
credibility to the model. If the CV had been 20%, for example,
then, for a mapping with a central value of 2.0, 95% of the studies
would have true mappings between 1.22 and 2.78. But, if the CV
was as high as, say, 40%, the 95% limits on study-speciﬁc
mappings would be 0.43 to 3.37, at which point one might
begin to question the usefulness of the concept of mapping,
and doubt the validity of our structural equation approach (3).
In the context of HTA, high precision and lack of variability in
mappings is obviously desirable, and also potentially in trial
design [35].
A number of methods for the synthesis of multiple outcomes
have been proposed, with different objectives and different
scope. If different test instruments are considered to measure
approximately the same underlying construct, as in tests of
depression, or social anxiety, a strategy often adopted in evidence
synthesis is to standardize treatment effects by dividing through
by the sample SD [11]. This has been strongly criticized [46].
Division by the sample SD, while not contributing to bias, will
contribute extra heterogeneity to treatment effects, especially
when based on small samples. Second, the population SDs often
differ markedly, and trial designers may select a narrow group of
patients to increase the probability of detecting a “signiﬁcant”
effect. This will exaggerate standardized effects and introduce
further heterogeneity.
Our approach allows reporting the pooled result on any of the
original clinical scales, as recommended in the Cochrane Hand-
book [39], but without the problems created by standardization.
Also, unlike standardization, it is possible to incorporate infor-
mation from a far wider range of tests, not just those apparently
measuring the same construct, and without assuming that tests
are equally sensitive to treatment, which appears to be an
implicit assumption in standardization.
A quite different approach attempts to “borrow strength”
across outcomes by ﬁtting multivariate normal models to multi-
ple continuous outcomes [13–18]. The extent of “borrowing
strength” is usually very small unless data are missing on one
or more outcomes, in which case these models can improve on
the precision of the univariate estimates [14,15]. The models used
here represent a special case of these multivariate normal
models in which treatment effects on all outcomes are the same
within a constant (ﬁxed mapping), or similar (random mapping).
At the within-trial level, both approaches have the same like-
lihood and estimate the same number of parameters per trial.
Whether or not the mapping method borrows strength more
effectively between trials awaits a more detailed analysis. It
seems likely, however, that this will be the case because there
are only two between-trial variance parameters to estimate,
rather than one variance parameter per outcome. The critical
point, however, is that multivariate normal meta-analysis does
not generate mappings at all, let alone mappings that are
consistent with treatment effects. Furthermore, if multivariate
normal is used and mapping is required, the mapped parameters
will not be consistent with the evidence synthesis.
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Fig. 1 – Residuals of estimates for treatment effect measured on six instruments: 1) Pain-VAS; 2) BASFI; 3) BASDAI; 4) ASQOL;
5) SF-36 PCS; and 6) SF-36 MCS under the random mapping model. ASQOL, Ankylosing Spondylitis Quality of Life scale;
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; SF-36
MCS, short-form 36 health survey mental component summary; SF-36 PCS, short-form 36 health survey physical component
summary; VAS, visual analogue scale.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 2 8 0 – 2 8 7 285Our proposals also have implications for the common practice
of “mapping” an estimated treatment effect on a DSM into an
estimated treatment effect on another instrument, usually a
generic HRQOL, when the latter has not been measured in a trial
[19,20]. Mappings based on trial-generated treatment effects have
not, it appears, been envisaged so far in the literature. Instead
mappings have been estimated from cohort studies, usually
from cross-sectional data in which patients with the condition
in question are assessed on both the DSM and the generic
instruments. The resulting estimates are then applied to a DSM
treatment effect to provide a treatment effect on the
generic HRQOL.
The common use of ordinary least squares regression to
estimate mappings in cohort studies has been criticized on
grounds that resulting estimates are neither transitive nor
invertible [22]. The extensive literature on test equating and
aligning (see, e.g., Dorans et al. [47] and Kolen and Brennan
[48]) also asserts that invertability is a requirement and that this
rules out ordinary least squares. But regardless of the method-
ology used, one can question whether it is even theoretically
possible to identify mappings between treatment effects in studies
in which causal treatment effects cannot be identiﬁed, and in
which treatments might not feature at all. As far as we know, the
precise assumptions under which this could be achieved have
never been elaborated.
Our clear ﬁnding of across-study heterogeneity in mappings,
although at a relatively low level, runs counter to assumptions
implicit in the health economics literature that mappings are
constant across studies. As a result, it is likely that the precision
attributed to estimated mappings used in HTA has been quite
severely exaggerated.Perhaps a greater weakness in the way mappings are imple-
mented in HTA practice is the reliance placed on mapping from,
most commonly, just one DSM to the target generic instrument.
In many cases, most of the trial evidence, including treatment
effects on the target generic scale itself, is ignored. For ankylosing
spondylitis, different mappings, usually various linear equations
in Bath Ankylosing Spondylitis Disease Activity Index and Bath
Ankylosing Spondylitis Functional Index, derived from either
cohorts or trials treated as observational cohorts, have been used
in cost-effectiveness models [49]. Inefﬁcient use of trial data,
mapping a single DSM into the EQ-5D questionnaire scale when
several are available, can be found in economic models of
Alzheimer’s disease [50,51] or psoriatic arthritis [52].
In contrast, use of the trial evidence on all trial outcomes, as
illustrated here, allows us to pool treatment effect information
over all scales, the validity of which is supported here by the low
CV, and at the same time provides a joint and unbiased mapping
that all investigators can use, which is coherently and trans-
parently derived from the same, noncontroversial, trial-based
evidence used to estimate treatment effects themselves. Further-
more, unlike mappings derived from ordinary least squares
regression, these approaches will not routinely underestimate
effects of treatments on generic HRQOL scales [22].
An important limitation of the method is that it requires that
the target HRQOL scale, such as the EQ-5D questionnaire, is one
of the outcome measures in a connected network of outcomes. In
our example, there is a lack of trial data on the EQ-5D question-
naire, and so no mapping to the EQ-5D questionnaire can be
derived. One should remember that not all mapping is based on
linear relationships: in some clinical areas, studies estimating
mean EQ-5D questionnaire scores in “mild,” “moderate,” and
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 2 8 0 – 2 8 7286“severe” patients, as deﬁned by a continuous scale, are used to
assess the effect of treatment on the EQ-5D questionnaire. There
would be advantages to using simultaneous mapping and syn-
thesis of all available DSMs, as advocated here, to estimate the
proportion of patients in each severity group following treatment.
Alternatively, if the target HRQOL is not part of the network of
outcomes, it is open to investigators to use geometric regression
[22] or other methods [47,48] to map between the EQ-5D ques-
tionnaire and one of the outcomes in the network.
In applications it will be important to limit sources of hetero-
geneity that could generate variation in mappings. The assump-
tion of multivariate normality in treatment effects, and hence
linearity of treatment effects, is fairly standard for the continu-
ous, or commonly interpreted as continuous, patient- and
clinician-reported outcomes for which the method is intended.
But there is an implicit assumption of approximately linear
relations between the underlying scales at the patient level. If
two measures are not linearly related, the ratios of mean effects
will vary across the measurement spectrum. This will show up as
heterogeneity in mapping ratios. This is the likely mechanism of
heterogeneity in mappings, and reminds us that all kinds of
evidence synthesis give better results in homogeneous sets of
patients. Efforts to apply these methods to network meta-
analyses [24] involving heterogeneous classes of treatment may
also be a source of additional heterogeneity in mappings, if, for
example, a subset of the test instruments were more sensitive to
particular classes of treatments. The usefulness of these methods
will begin to be clear only after they have been applied to a wide
range of data sets on different conditions.
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